Jefferies Cuts Price Target on Parexel (PRXL) to $67 Following Weak 1Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- Oil slips ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
PAREXEL International Reports First Quarter Fiscal Year 2017 Results and Announces New Share Repurchase Program
October 26, 2016 4:02 PM EDTFirst Quarter Fiscal Year 2017 Results (compared to First Quarter Fiscal Year 2016)
GAAP diluted earnings per share of $0.75, up 66.7%; adjusted earnings per share of $0.76, up 8.6% Service revenue of $500.9 million, down 2.2%; constant currency revenue decline of 2.4% Gross new business of $930 million Company guides to GAAP EPS of $3.55-$3.89 and adjusted EPS of $3.71-$4.05 for Fiscal Year 2017 Board approved new $200 million share repurchase programBOSTON--(BUSINESS WIRE)-- PAREXEL International Corporation (NASDAQ: PRXL) today reported... More
BioPharm Insight Releases CRO Report on Clinical Trial Activity in 3rd Quarter
October 25, 2016 8:30 AM EDTReport ranks PRA Health Sciences and INC Research as the most active CROs
NEW YORK--(BUSINESS WIRE)-- BioPharm Insight (BPI), the most comprehensive life science market intelligence and analytics solution, today released its exclusive... More
